What Happened?
Medford, MA-based PixarBio Promoted Jason Criscione as Chief Technology Officer
About the Company
Cofounded by Frank M. Reynolds, MIT`s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson`s disease, and spinal cord injury.
About the Person
Jason Criscione leads the research and development of PixarBio’s Drug Delivery Systems. Winner of the “PixarBio Inventor of the Year” Dr. Criscione brings over a decade of drug delivery and materials science expertise to PixarBio. Jason leads the discovery, development, GMP scale-up, and clinical translation of versatile drug delivery platforms designed to treat a myriad of neurological conditions, including acute, post-operative, and chronic pain. Dr. Criscione received his PhD in Biomedical Engineering from Yale University and his research lies at the interface of materials science, immunotherapy and medical imaging and is published in peer-reviewed, scientific journals, including, Nature Materials, Biomaterials, JACS and ACS Nano. He also holds a BA in Chemistry with a concentration in Neuroscience from Oberlin College, a MS in Physical Chemistry from Michigan State University, and a MS in Biomedical Engineering from Yale University.
Info Source
News
Short Profile